Detalles de la búsqueda
1.
Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance.
AIDS Res Ther;
20(1): 3, 2023 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36604746
2.
Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy.
J Infect Dis;
223(3): 462-470, 2021 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32603416
3.
Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS).
J Infect Dis;
221(9): 1407-1415, 2020 04 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31135883
4.
Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings.
Clin Infect Dis;
71(7): e170-e177, 2020 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31724034
5.
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.
PLoS Pathog;
13(4): e1006285, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28426825
6.
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART.
J Infect Dis;
218(2): 234-238, 2018 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29529230
7.
Reply to Bottanelli et al.
J Infect Dis;
225(11): 2051-2052, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35381084
8.
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
Lancet;
387(10024): 1198-209, 2016 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27025337
9.
Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
Antimicrob Agents Chemother;
59(6): 3399-405, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25824215
10.
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
N Engl J Med;
365(16): 1482-91, 2011 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-22010914
11.
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
Clin Infect Dis;
57(4): 586-93, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23592830
12.
Antiretroviral therapies in women after single-dose nevirapine exposure.
N Engl J Med;
363(16): 1499-509, 2010 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-20942666
13.
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group.
PLoS One;
18(2): e0281580, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36780493
14.
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
PLoS Med;
9(6): e1001236, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22719231
15.
Brief Report: No Differences Between Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297).
J Acquir Immune Defic Syndr;
89(2): 178-182, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34693933
16.
Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.
AIDS Res Hum Retroviruses;
38(6): 510-517, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35323030
17.
Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings.
Open Forum Infect Dis;
9(7): ofac325, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35899273
18.
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
J Int AIDS Soc;
25(6): e25905, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36039892
19.
Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.
AIDS Res Hum Retroviruses;
37(6): 489-501, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33472545
20.
Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings.
AIDS;
35(9): 1439-1449, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33831905